Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


March 29, 2015 12:52 AM ET

Biotechnology

Company Overview of Boston Biomedical, Inc.

Company Overview

Boston Biomedical, Inc. operates as a biotechnology company that develops cancer therapeutics for patients suffering from cancer. It offers 10 discovery-stage oncology programs and 5 clinical-stage oncology programs including BBI608, a cancer stem cells (CSC) inhibitor in Phase III trials in North America and Australasia; and BBI503, a CSC kinase inhibitor in Phase I trials in North America. The company was founded in 2006 and is based in Cambridge, Massachusetts. As of April 24, 2012, Boston Biomedical, Inc. operates as a subsidiary of Dainippon Sumitomo Pharma Co., Ltd.

640 Memorial Drive

Cambridge, MA 02139

United States

Founded in 2006

Phone:

617-674-6800

Key Executives for Boston Biomedical, Inc.

Founder, Chief Executive Officer, President, Chief Medical Officer and Director
Age: 49
Chief Operating Officer and Vice President
Chief Commercial Officer and Executive Vice President
Age: 55
Vice President of Product Development & Business Affairs
Compensation as of Fiscal Year 2014.

Boston Biomedical, Inc. Key Developments

Boston Biomedical, Inc. and Boston Biomedical Pharma Inc. Appoint Patricia S. Andrews as Executive Vice President and Chief Commercial Officer

Boston Biomedical, Inc. and Boston Biomedical Pharma Inc., collectively "Boston Biomedical", announced that it has appointed Patricia S. Andrews as Executive Vice President and Chief Commercial Officer as it begins strategic planning and preparations for the commercialization of its cancer stem cell inhibitors with its lead asset, BBI608, currently in a global Phase 3 clinical trial for metastatic colorectal cancer. Ms. Andrews most recently served as Executive Vice President and Chief Commercial Officer at Incyte Corporation.

Boston Biomedical, Inc. Opens of its Cambridge Headquarters

Boston Biomedical, Inc. announced the relocation of its headquarters to Cambridge, Massachusetts. The new, 64,000-square-foot facility is located at 640 Memorial Drive, situated at the epicenter of the region's life science and technology clusters. With a new and support from DSP, Boston Biomedical aims to continue to leverage its scientific excellence and leadership in order to advance the development of novel cancer therapeutics.

Similar Private Companies By Industry

Company Name Region
Nucleonics, Inc. United States
X-BODY, Inc United States
Peptineo, LLC United States
Aventis Cambridge Genomics Center LLC United States
Allergan Specialty Therapeutics, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Boston Biomedical, Inc., please visit www.bostonbiomedical.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.